In the News
December 07, 2022
Dr. Rezvani has been named as "20 of the Top Women Leading Biopharma R&D" - Special Report 2022: Meet 20 women blazing trails in biopharma R&D
November 10, 2022
New cancer therapy takes personalized medicine to a new level - USA Today
October 5, 2021
Katy Rezvani, M.D., Ph.D., has been named the recipient of MD Anderson’s 2021 Excellence in LEADership. “Dr. Rezvani maintains an open-door policy, encouraging communication with team members no matter what their needs are, or what time they need to reach her. Dr. Rezvani listens to us, and provides kind and constructive advice, building each one of us to be stronger in all we do. It is inspiring to see how much she cares about her team, and how, by always communicating with her team, she encourages each one of us during great times and during challenging times.
September 24, 2021
Katy Rezvani, M.D., Ph.D., has been named the recipient of the 2021 Texas Business Woman’s Award. This honor is given annually to MD Anderson faculty who have attained significant achievements in cancer research or cancer treatment, and it is sponsored by the Texas Business and Professional Women’s Foundation.
August 27, 2021
Katy Rezvani, M.D., Ph.D., has been named recipient of MD Anderson’s 2021 Faculty Achievement Award by the Faculty Senate committee for The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research
July 15, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy: Cell Reports
May 17, 2021
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
April 30, 2021
Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants (news-medical.net)
November 5, 2019
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform. Watch the YouTube video.